Parsaclisib Added to Ruxolitinib Decreases Spleen Volume and Improves Symptom Scores in Myelofibrosis

Add-on parsaclisib with ruxolitinib resulted in decreased spleen volume and improved symptom assessment scores in patients with myelofibrosis.

Related Keywords

Kansas City ,Kansas ,United States ,Abdulraheem Yacoub ,Ku Medical Center ,Myelofibrosis Symptom Assessment Form ,Hematologic Malignancies ,Cellular Therapeutics ,Patient Global Impression ,Parsaclisib With Ruxolitinib ,Patients With Myelofibrosis ,D ,